187 related articles for article (PubMed ID: 11220666)
1. Biomarkers and surrogacy: relevance to chemoprevention.
Kensler TW; Davidson NE; Groopman JD; Muñoz A
IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
3. Surrogate end-point biomarkers in chemopreventive drug development.
Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
[TBL] [Abstract][Full Text] [Related]
4. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in cancer chemoprevention. Workshop report.
IARC Sci Publ; 2001; 154():1-12. PubMed ID: 11220649
[No Abstract] [Full Text] [Related]
6. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
[No Abstract] [Full Text] [Related]
7. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
[TBL] [Abstract][Full Text] [Related]
8. Carcinogen biomarkers for lung or oral cancer chemoprevention trials.
Hecht SS
IARC Sci Publ; 2001; 154():245-55. PubMed ID: 11220664
[TBL] [Abstract][Full Text] [Related]
9. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
10. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
Sanner T; Dybing E
Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
[TBL] [Abstract][Full Text] [Related]
11. Progress in clinical chemoprevention.
Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
[TBL] [Abstract][Full Text] [Related]
12. The role of chemoprevention in cancer control.
Greenwald P; Kelloff GJ
IARC Sci Publ; 1996; (139):13-22. PubMed ID: 8923016
[TBL] [Abstract][Full Text] [Related]
13. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
15. Biological relevance of adduct detection to the chemoprevention of cancer.
Sharma RA; Farmer PB
Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
[TBL] [Abstract][Full Text] [Related]
16. Development of difluoromethyl-ornithine and Bowman-Birk inhibitor as chemopreventive agents by assessment of relevant biomarker modulation: some lessons learned.
Meyskens FL
IARC Sci Publ; 2001; 154():49-55. PubMed ID: 11220668
[TBL] [Abstract][Full Text] [Related]
17. [The use of biomarkers in cancer prevention].
Tompa A
Orv Hetil; 2006 Apr; 147(14):627-36. PubMed ID: 16711369
[TBL] [Abstract][Full Text] [Related]
18. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
[TBL] [Abstract][Full Text] [Related]
19. Carcinogen-DNA and protein adducts: biomarkers for cohort selection and modifiable endpoints in chemoprevention trials.
Kensler TW; Groopman JD
J Cell Biochem Suppl; 1996; 25():85-91. PubMed ID: 9027603
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of human trial design.
Buiatti E
IARC Sci Publ; 1996; (139):261-9. PubMed ID: 8923036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
